Search results for "Muscle invasive"

showing 3 items of 23 documents

MP26-19 A PROSPECTIVE STUDY ON THE INFLUENCE ON RECURRENCE OF QUITTING CIGARETTE SMOKING AT DIAGNOSIS OF PRIMARY NON MUSCLE INVASIVE BLADDER CANCER

2015

medicine.medical_specialtyBladder cancerCigarette smokingbusiness.industryUrologyInternal medicinemedicineNon muscle invasiveProspective cohort studybusinessmedicine.diseaseSurgeryJournal of Urology
researchProduct

Non-muscle invasive bladder cancer: Are epicrises the ‘Bermuda Triangle’ of information transfer?

2017

Introduction The aim of the study was to collect information regarding the quality of communication of risk-determining factors or risk profile, and the guideline conformity of recommendations for adjuvant treatment in patients with non-muscle invasive bladder cancer (NMIBC) between clinical and ambulatory urologists. Material and methods At three German urological clinics during the period between 2012-2014, epicrises of 1,033 NMIBC-patients were retrospectively summarised to 505 tumour episodes (tumour resection including any re-resections) and analysed regarding the endpoints 1) risk profile is explicitly named or recorded risk factors are sufficient for the determination of risk profile…

medicine.medical_specialtyOriginal PaperProcess Assessment (Health Care)Bladder cancerbusiness.industryTumor resection030232 urology & nephrologyGuideline complianceGuideline adherenceGeneral MedicineGuidelinemedicine.diseaseLogistic regression03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineGermanyAmbulatorymedicineIn patientNon muscle invasivebusinessurinary bladder neoplasmsCentral European Journal of Urology
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct